This piece breaks down CME Group, the world's biggest derivatives exchange, which profits from market volatility. Guest Adam Chandler sees a strong moat: network effects from deep liquidity and a legal lock-in that keeps futures clearing exclusive to CME. He's bullish, arguing volatility will return. Key holdings: CME (over 70% margins), ICE (rival, but different products), and FMX (a new exchange with near-zero trading volume).
Guest: Adam Chandler, Co-Portfolio Manager at Claremont Global. Theme: Deep dive into CME Group's business model, moat, and growth logic as the world's largest derivatives exchange. Most impactful takeaway of the episode: CME's uniqueness lies in its option value of "benefiting from volatility" — very few businesses can directly and legitimately profit from market volatility like it does (Adam Chandler points out, "CME is most unique due to the value of the optionality within the business. This is a business that truly benefits from volatility").
Adam Chandler argues that CME's competitive advantage stems from three mutually reinforcing elements: the network effects of liquidity, the legal lock-in from vertical integration of trading and clearing, and the historical benchmark product status.
> Reader's Note: As an investor in CME, the guest emphasizes its "natural monopoly" characteristics. Readers should be aware that this is a position-holder's perspective, and competition and regulatory risks may be underestimated.
Adam Chandler points out that CME's growth is inherently "volume-driven" rather than "price-driven," and that incremental profits are extremely high (approximately 90% incremental margins), thanks to its fixed cost structure.
| Growth Driver | Short-Term Impact | Long-Term Impact |
|---|---|---|
| Volatility | Core driver | Influenced by underlying asset size and cycles |
| Underlying asset size (e.g., U.S. Treasury outstanding) | Weaker | Strong correlation; stock growth drives contract demand |
| Client expansion (non-U.S./retail) | Ongoing | Primary incremental source |
| New products/micro contracts | Marginal contribution | Expands addressable market, but core revenue still from legacy products |
Adam Chandler argues that CME has extremely high competitive moats, having historically repelled 8 substantial challenges, and the most watched challenger FMX is currently facing difficulties.
Adam Chandler lists four major risks for CME, pointing out that — despite the excellent management team, some risks are difficult to quantify.
1. Return of low-volatility environment: If the interest rate environment returns to low volatility, it will put short/medium-term pressure on trading volumes. However, Chandler believes that "volatility can only be suppressed for a period of time," and in the medium to long term, the US deficit (6%+ of GDP, increasing by about $2 trillion annually) and the outstanding Treasury debt (about $29 trillion) determine that volatility cannot disappear permanently.
2. Operational incidents: Although CME is widely recognized as best in class, history has not been without precedents: in 2018, Nasdaq Nordic Clearing lost over €100 million due to a single trader default; in 2022, the London Metal Exchange (LME) had billions of dollars in trades canceled due to risk control failures in nickel contracts, triggering lawsuits. CME's risk management is superior, but not infallible.
3. Cybersecurity: Not unique to CME, but its importance goes without saying.
4. Regulatory risk: Change is the norm, but Chandler believes that "structural regulatory reform of CME's core business would require very bold action from Congress," so the probability is low. CEO Terry Duffy has excelled in managing regulatory relationships, maintaining good communication with both parties.
> Key uncertainty: Can low volatility persist? Chandler's judgment that "volatility will eventually return" is not a consensus. In 2024-2025, the market has seen a certain degree of "normalization of low volatility." Readers should note the falsifiability of this judgment.
| Position | Guest Attitude | Key Data |
|---|---|---|
| CME Group | Bullish | Adjusted operating margin >70%, pre-tax margin >75%, profit per employee ~$1 million; cumulative dividends since 2012 of $29 billion (market cap at end of 2011 was only $17 billion) |
| Intercontinental Exchange (ICE) | Neutral (competitor, but limited product overlap) | Holds Brent crude oil contract; acquired mortgage business; has some substitutability with CME in certain areas |
| FMX (founded by Howard Lutnick) | Not bullish (challenger, extremely weak liquidity) | SOFR contract market share ~10 basis points (0.1%); has seen zero trading for an entire day |
| SIBO (CBOE) | Neutral (competitor, but different products) | Holds S&P index options, CME holds S&P futures and options |
| London Stock Exchange (LSEG) | Neutral (competitor, participates in swap clearing via subsidiaries) | Participates in FMX's clearing infrastructure |
| NASDAQ (Nordic clearing house) | Risk case | In 2018, lost over €100 million due to a single trader default |
| London Metal Exchange (LME) | Risk case | In 2022, risk control failure on nickel contract, cancelled billions of dollars in trades |
1. CME is a "long volatility" option, not an ordinary exchange (Adam Chandler). Support: It is difficult to find any other S&P 500 constituent that can so directly benefit from market volatility. However, extreme volatility (such as a crash) is also harmful.
2. CME's incremental profit logic: no new factories needed, just new trades (Adam Chandler). Support: fixed costs + low variable costs, each unit of incremental trade brings about a 90% marginal profit margin, which is also why the profit margin can remain above 70% for a long time.
3. "The real best" is liquidity, not low fees (Adam Chandler, for institutional clients). Support: In the U.S. Treasury futures market, clients pay about 50 cents per contract, but the minimum price change of the contract is $8 — the value of liquidity far exceeds the fee. CME has very little room to raise prices, but users can barely perceive it.
4. CME's clearing lock is a statutory moat, not a business choice (Adam Chandler). Support: Section 403 of the Dodd-Frank Act prohibits interoperable clearing of futures contracts, meaning CME's liquidity cannot be shared across multiple exchanges like stocks, which is the legal foundation of the vertical integration model.
5. Challengers are often completely abandoned in "crisis moments" (Adam Chandler). Support: During the tariff volatility in April 2025, CME's trading volume surged, while the volume of small exchanges like FMX dropped to zero. The deeper the liquidity, the more trust it wins under pressure.
6. CME's "growth formula" remains unchanged: volume > price, fixed costs > incremental costs (Adam Chandler). Support: CME's annual organic revenue growth rate is about 5%-8%, mainly from trading volume, not price increases. Pricing is complex and prudent, but the real growth lever is customer expansion and new products.
7. CME's capital allocation: dividends are core, acquisitions are rare (Adam Chandler). Support: Since 2012, CME has cumulatively paid $29 billion in dividends, while its market capitalization grew from $17 billion to $99 billion over the same period. The CEO prefers organic growth over entering new fields (such as mortgages) through acquisitions like ICE.
8. CME's self-created framework: the liquidity generation sequence of "real money → speculative money" (Adam Chandler, internalized from CME's competitive logic). Support: The liquidity base of a contract comes from the "real money" of industrial hedgers (such as farmers, corporations, banks), followed by speculators. New exchanges cannot attract enough real money, so liquidity can never scale up.